Zelira Therapeutics Limited
ZLDAF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.00 | 0.04 | -0.04 |
| FCF Yield | -100.73% | -110.69% | -48.96% | -118.30% |
| EV / EBITDA | -1.73 | -0.26 | -2.24 | -0.48 |
| Quality | ||||
| ROIC | 183.92% | -326.20% | -20.22% | -33.57% |
| Gross Margin | -122,400.15% | 10.83% | -1,068.03% | -371.02% |
| Cash Conversion Ratio | 1.35 | 0.12 | 1.30 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | -87.04% | -60.50% | -23.14% | – |
| Free Cash Flow Growth | -11.81% | 39.46% | 23.10% | -9.41% |
| Safety | ||||
| Net Debt / EBITDA | -0.53 | -0.15 | -0.04 | 0.19 |
| Interest Coverage | -9.71 | -8.03 | -84.82 | -249.13 |
| Efficiency | ||||
| Inventory Turnover | 1.68 | 0.07 | 2.30 | 3.71 |
| Cash Conversion Cycle | 1,258.11 | -8,528.82 | -23.43 | 83.25 |